CN117883493A - Traditional Chinese medicine composition for treating gastric spasmolytic polypeptide expression metaplasia and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating gastric spasmolytic polypeptide expression metaplasia and preparation method and application thereof Download PDFInfo
- Publication number
- CN117883493A CN117883493A CN202410148797.3A CN202410148797A CN117883493A CN 117883493 A CN117883493 A CN 117883493A CN 202410148797 A CN202410148797 A CN 202410148797A CN 117883493 A CN117883493 A CN 117883493A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- parts
- medicine composition
- gastric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 239000003814 drug Substances 0.000 title claims abstract description 71
- 230000002496 gastric effect Effects 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 206010054949 Metaplasia Diseases 0.000 title abstract description 19
- 230000015689 metaplastic ossification Effects 0.000 title abstract description 17
- 230000014509 gene expression Effects 0.000 title description 10
- 108010088411 Trefoil Factor-2 Proteins 0.000 title description 6
- 102100039172 Trefoil factor 2 Human genes 0.000 title description 6
- 108010013137 spasmolytic polypeptide Proteins 0.000 title description 6
- 230000003902 lesion Effects 0.000 claims abstract description 27
- 241000132012 Atractylodes Species 0.000 claims abstract description 7
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 7
- 244000197580 Poria cocos Species 0.000 claims abstract description 7
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 7
- 235000008434 ginseng Nutrition 0.000 claims abstract description 7
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 6
- 235000011477 liquorice Nutrition 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000006187 pill Substances 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 238000004806 packaging method and process Methods 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- 241000208340 Araliaceae Species 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 6
- 239000011362 coarse particle Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000002390 rotary evaporation Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 229940100688 oral solution Drugs 0.000 claims 1
- 210000001156 gastric mucosa Anatomy 0.000 abstract description 31
- 210000004907 gland Anatomy 0.000 abstract description 23
- 230000006378 damage Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 13
- 208000027418 Wounds and injury Diseases 0.000 abstract description 10
- 208000014674 injury Diseases 0.000 abstract description 10
- 230000036542 oxidative stress Effects 0.000 abstract description 5
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 abstract description 2
- 230000036210 malignancy Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 230000009466 transformation Effects 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 27
- 229960001603 tamoxifen Drugs 0.000 description 18
- 239000003642 reactive oxygen metabolite Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 210000002784 stomach Anatomy 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 8
- 108091006112 ATPases Proteins 0.000 description 7
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 7
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 7
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 102100028006 Heme oxygenase 1 Human genes 0.000 description 6
- 241000483399 Ipimorpha retusa Species 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 5
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 206010017758 gastric cancer Diseases 0.000 description 5
- 230000004792 oxidative damage Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000012490 blank solution Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010064912 Malignant transformation Diseases 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000036212 malign transformation Effects 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001711 oxyntic cell Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000020238 sunflower seed Nutrition 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating gastric mucosa metaplasia, and a preparation method and application thereof. The traditional Chinese medicine composition comprises the following traditional Chinese medicine components in parts by weight: 9-18 parts of ginseng, 9-18 parts of bighead atractylodes rhizome, 9-18 parts of poria cocos, and 6-9 parts of liquorice (stir-fried). The traditional Chinese medicine composition prepared by the invention can relieve gastric mucosa gland injury, strengthen antioxidation capability, protect gastric mucosa glands, prevent the fate of further transformation of gastric mucogenesis lesion to malignancy by relieving oxidative stress injury, and is safe and has no obvious toxic or side effect.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for treating gastric mucogenesis lesions, and a preparation method and application thereof.
Background
Gastric mucogenic lesions refer to alterations in the normal cell type of the gastric mucosa, usually due to chronic irritation or injury over time. It is currently widely believed that gastric mucosal metaplasia may be related to factors such as inflammation, infection, atrophy and the like, and long-term metaplasia may cause gastric cancer, which is one of the recognized important premalignant lesions.
Studies have shown that spasmolytic polypeptide expression metaplasia (spasmolytic polypeptide expressing metaplasia, SPEM) plays an important role in the development and progression of gastric cancer as another metaplasia mode than intestinal metaplasia. Oxidative damage to gastric mucosal tissue under the sustained stimulus of chronic inflammatory response may occur, and SPEM may be converted from SPEM to incomplete intestinal metaplasia, which may be one of the mechanisms of gastric adenocarcinoma. Since the occurrence of SPEM may be closely related to gastric mucosal tissue carcinogenesis, significant academic attention has been drawn in recent years. However, there is currently a lack of research and methods for blocking SPEM to further prevent this pathological process of gastric mucolasis turning to malignant transformation.
Therefore, developing and searching for effective treatment methods will help early prevention and treatment of gastric cancer, possibly contributing to reducing the incidence and mortality of intestinal-type gastric cancer.
Disclosure of Invention
In view of the problems existing in the prior art, the invention provides a traditional Chinese medicine composition for treating gastric mucogenesis lesions, and a preparation method and application thereof. In animal experiments, a mouse model of gastric mucosa metaplasia, namely spasmolytic polypeptide expression metaplasia, is constructed by using tamoxifen administration, and a traditional Chinese medicine composition commonly used for treating spleen and stomach qi deficiency syndrome is verified.
Spasmolytic polypeptide expression is the second metaplasia associated with intestinal gastric cancer and is considered one of the possible precancerous lesions of gastric mucosal tissue, and is currently receiving increasing attention. In order to further prevent the pathological process of the gastric mucosis turning to malignant transformation, the invention provides a traditional Chinese medicine composition and a preparation method thereof.
A traditional Chinese medicine composition for treating gastric mucosa metaplasia comprises the following traditional Chinese medicine components in parts by weight: 9-18 parts of ginseng, 9-18 parts of bighead atractylodes rhizome, 9-18 parts of poria cocos, and 6-9 parts of liquorice (stir-fried).
The traditional Chinese medicine composition for treating gastric mucogenesis lesions can be prepared into decoction, pills, ointment, tablets, capsules, granules, oral solutions, powder and the like.
The preparation method of the traditional Chinese medicine composition for treating gastric mucogenesis lesions comprises the following steps when the traditional Chinese medicine composition is an extract: (1) weighing the raw materials according to the proportion; (2) Soaking the weighed medicinal materials in 70% ethanol with volume of about 3 times of that of the medicinal materials for 12 hours, filtering with filter paper and a funnel, retaining filtrate, and discarding filter residues; (3) And putting the obtained filtrate on a rotary evaporator for rotary evaporation, taking out when the filtrate is in a viscous wall-hanging state, and putting the filtrate in a hot air sterilizing box for evaporating residual alcohol.
The preparation method of the traditional Chinese medicine composition for treating gastric mucogenesis lesions comprises the following steps when the traditional Chinese medicine composition is powder: taking the medicine combination according to the weight parts, crushing, sieving with a 10-mesh sieve and a 50-mesh sieve, continuously crushing coarse particles which cannot pass through the 10-mesh sieve, and taking powder between the 10-mesh sieve and the 50-mesh sieve; mixing the above materials, packaging into a packaging bag, and sealing. When the medicine is needed to be taken, 150-200 ml of warm boiled water is directly used for taking the powder.
The preparation method of the traditional Chinese medicine composition for treating gastric mucogenesis lesions comprises the following steps when the traditional Chinese medicine composition is a pill: taking the above medicines according to the parts by weight, crushing, sieving with a 10-mesh and 50-mesh sieve, continuously crushing coarse particles which cannot pass through the 10-mesh sieve, taking powder between the 10-mesh sieve and the 50-mesh sieve, and sun-drying; taking a proper amount of honey, decocting slowly with small fire, stirring, taking out impurities and floating foam on the surface, after the temperature is raised to 116-119 ℃, mixing with the medicinal powder uniformly (adding according to the proportion of 1:1.2-1.5), rubbing into pills, and packaging and storing the prepared honeyed pills in sealed bags after the honeyed pills are dried at room temperature, wherein the pills are convenient to take and have lasting medicinal effect.
The preparation method of the traditional Chinese medicine composition for treating gastric mucogenesis lesions comprises the following steps when the traditional Chinese medicine composition is a decoction: weighing the raw materials according to the proportion; soaking the raw materials in 8-12 times of water for 30min, heating to boil and keeping slight boiling, and separating to obtain a first decoction and residue; adding water 8-10 times of the total weight of the raw materials into the residue obtained after the first decoction, heating to boil, keeping micro-boiling, and separating to obtain a second decoction and residue; and combining the first decoction and the second decoction to obtain the water decoction.
The invention relates to an application of a pharmaceutical composition for treating gastric mucogenesis lesions in preparing medicines for treating gastric mucogenesis lesions.
The traditional Chinese medicine composition for treating gastric mucosa metaplasia provided by the invention has the effects of warming and invigorating qi, strengthening spleen and nourishing stomach, and the ginseng is taken as a monarch drug in the formula; ministerial drugs are white atractylodes rhizome with bitter taste and warm nature, which can strengthen the spleen and dry dampness, strengthen the qi-tonifying and transportation-assisting ability; with the sweet and bland poria cocos, spleen strengthening and dampness excreting are matched, and the spleen strengthening and dampness excreting effects are good; licorice root, radix Glycyrrhizae Praeparata, has the effects of invigorating qi, regulating the middle warmer, and regulating the functions of the other drugs. The four medicines are compatible, and have the effects of replenishing qi and strengthening spleen; the herbs in this recipe are neutral in nature, mild in taste, tonic without severity, warm without dryness, and neutral in nature.
Compared with the prior art, the invention has the following beneficial effects.
The traditional Chinese medicine composition for treating gastric mucosa metaplasia provided by the invention can relieve gastric mucosa gland injury, strengthen antioxidation capability by relieving oxidative stress injury, protect gastric mucosa gland, prevent the fate of further transformation of gastric mucosa metaplasia to malignancy, and is safe and has no obvious toxic and side effects. The Chinese medicinal composition can be effectively prevented and treated, and the medicinal composition adopts natural Chinese herbal medicines, so that various dosage forms can be provided, and the Chinese medicinal composition is convenient to use.
Drawings
The pharmaceutical composition of figure 1 improves tamoxifen-induced gastric mucosal gland lesions after pretreatment treatment.
Figure 2 is a graph showing improvement in tamoxifen-induced gastric mucosal gland lesions following treatment with a pharmaceutical composition.
Figure 3 improves tamoxifen-induced H+/K+ ATPase in gastric mucosal gland wall cells following pretreatment treatment with the herbal composition.
Figure 4 improves tamoxifen-induced reactive oxygen species ROS levels in gastric mucosal glands following pretreatment treatment with the pharmaceutical composition.
FIG. 5 Western bolt detection Model group and Chinese medicinal composition group show the expression levels of 8-oxo-dg, HO-1 and Nrf2 proteins in the stomach tissues of mice after tamoxifen induction for 0h, 6h, 24h, 48h and 72h respectively.
FIG. 6H & E staining observed the effects of heart, liver, double kidney histopathology in mice.
Detailed Description
The present invention is further illustrated below in conjunction with specific embodiments, it being understood that these embodiments are presented by way of illustration only and not limitation to the scope of the invention, and that modifications to the invention in its various equivalents will fall within the scope of the claims appended hereto.
A traditional Chinese medicine composition for treating gastric mucosa metaplasia comprises the following traditional Chinese medicine components in parts by weight: 9-18 parts of ginseng, 9-18 parts of bighead atractylodes rhizome, 9-18 parts of poria cocos, and 6-9 parts of liquorice (stir-fried).
The traditional Chinese medicine composition for treating gastric mucogenesis lesions can be prepared into decoction, pills, ointment, tablets, capsules, granules, oral solutions, powder and the like.
The preparation method of the traditional Chinese medicine composition for treating gastric mucogenesis lesions comprises the following steps when the traditional Chinese medicine composition is an extract: (1) weighing the raw materials according to the proportion; (2) Soaking the weighed medicinal materials in 70% ethanol with volume of about 3 times of that of the medicinal materials for 12 hours, filtering with filter paper and a funnel, retaining filtrate, and discarding filter residues; (3) And putting the obtained filtrate on a rotary evaporator for rotary evaporation, taking out when the filtrate is in a viscous wall-hanging state, and putting the filtrate in a hot air sterilizing box for evaporating residual alcohol.
The preparation method of the traditional Chinese medicine composition for treating gastric mucogenesis lesions comprises the following steps when the traditional Chinese medicine composition is powder: taking the medicine combination according to the weight parts, crushing, sieving with a 10-mesh sieve and a 50-mesh sieve, continuously crushing coarse particles which cannot pass through the 10-mesh sieve, and taking powder between the 10-mesh sieve and the 50-mesh sieve; mixing the above materials, packaging into a packaging bag, and sealing. When the medicine is needed to be taken, 150-200 ml of warm boiled water is directly used for taking the powder.
The preparation method of the traditional Chinese medicine composition for treating gastric mucogenesis lesions comprises the following steps when the traditional Chinese medicine composition is a pill: taking the above medicines according to the parts by weight, crushing, sieving with a 10-mesh and 50-mesh sieve, continuously crushing coarse particles which cannot pass through the 10-mesh sieve, taking powder between the 10-mesh sieve and the 50-mesh sieve, and sun-drying; taking a proper amount of honey, decocting slowly with small fire, stirring, taking out impurities and floating foam on the surface, after the temperature is raised to 116-119 ℃, mixing with the medicinal powder uniformly (adding according to the proportion of 1:1.2-1.5), rubbing into pills, and packaging and storing the prepared honeyed pills in sealed bags after the honeyed pills are dried at room temperature, wherein the pills are convenient to take and have lasting medicinal effect.
The preparation method of the traditional Chinese medicine composition for treating gastric mucogenesis lesions comprises the following steps when the traditional Chinese medicine composition is a decoction: weighing the raw materials according to the proportion; soaking the raw materials in 8-12 times of water for 30min, heating to boil and keeping slight boiling, and separating to obtain a first decoction and residue; adding water 8-10 times of the total weight of the raw materials into the residue obtained after the first decoction, heating to boil, keeping micro-boiling, and separating to obtain a second decoction and residue; mixing the first decoction and the second decoction to obtain oral water decoction.
Example 1.
A Chinese medicinal composition for treating gastric mucosa metaplasia comprises the following raw materials: 9 parts of ginseng, 9 parts of bighead atractylodes rhizome, 9 parts of poria cocos, and 9 parts of liquorice (stir-fried).
The preparation method of the traditional Chinese medicine composition extract comprises the following steps: (1) weighing the raw materials according to the proportion; (2) Soaking the weighed medicinal materials in 70% ethanol with volume of about 3 times of that of the medicinal materials for 12 hours, filtering with filter paper and a funnel, retaining filtrate, and discarding filter residues; (3) And putting the obtained filtrate on a rotary evaporator for rotary evaporation, taking out when the filtrate is in a viscous wall-hanging state, and putting the filtrate in a hot air sterilizing box for evaporating residual alcohol.
Example 2 effect verification.
1. And (3) experimental animals.
Male C57BL/6 mice of 6-7 weeks old, experimental animal license number: SCXK (Su) 2023-0009. Raising in clean animal house at 20+ -24deg.C and relative humidity 55+ -5%, and alternately illuminating and cooling for 12 hr to obtain food and water. Animal experiments have been ethically examined by animal experiments at university of chinese medical science.
2. Experimental drugs.
The traditional Chinese medicine composition of example 1, tamoxifen (Toronto Research Chemicals Inc, cat#T 00600), was prepared with a mixed solvent of absolute ethanol and sunflower seed oil in a volume ratio of 1:9, and the final concentration was 25mg/ml.
3. Mouse SPEM model construction and dosing.
(1) Preparing a sterilized 1.5ml centrifuge tube, adding 900 mu l of sterilized sunflower seed oil into the centrifuge tube A, weighing 25mg of tamoxifen into the other 1.5ml centrifuge tube B, adding 100 mu l of absolute ethyl alcohol into the centrifuge tube B, performing ultrasonic crushing until the solid is completely dissolved, transferring the mixed solution in the centrifuge tube B into the centrifuge tube A, rapidly and uniformly shaking, and finally preparing the mixed solution of 25mg/ml tamoxifen. Conversion was performed at a clinical equivalent dose of 60kg for adults: the administration dosage of the traditional Chinese medicine composition of the mice is 5.46 g/kg.d after conversion.
(2) After C57BL/6 mice were fed adaptively for one week, they were randomly divided into 6 groups according to a random number table, and into pretreatment and no pretreatment regimen. In each protocol, a Control group, a Model group, and a Chinese medicinal composition group were set, 10 groups each (n=10), and 5 cages each. In the preprocessing scheme, the Control group and the Model group are subjected to ddH 2 2, performing gastric lavage treatment for 8 days by O (10 mu l/g multiplied by the weight of the mouse), performing treatment by a traditional Chinese medicine composition group by a traditional Chinese medicine composition (5.46 g/kg.d) for 8 days, and performing intraperitoneal injection for 3 days by a Model group and a traditional Chinese medicine composition group pretreatment according to tamoxifen (10 mu l/g multiplied by the weight of the mouse) with a final concentration of 25mg/ml on the 6 th day; control group pretreatment was performed on day 6 with blank solution (ddH 2 O) intraperitoneal injection for 3 days. The Model group and the Chinese medicine combination group are subjected to final concentration in the pretreatment-free schemeTamoxifen (10 μl/g×mouse body weight) at 25mg/ml was intraperitoneally injected for 3 days, and Control group was subjected to blank solution (ddH 2 O) intraperitoneal injection for 3 days for modeling; then the Control group and Model group are ddH 2 Lavage treatment of O (10 μl/g×mouse body weight) for 3 days; the Chinese medicinal composition is treated with the Chinese medicinal composition (5.46 g/kg.d) for 3 days.
4. Experimental methods.
After the completion of the administration, the heart, liver, double kidney and stomach tissues are dissected and separated, and hematoxylin is adopted respectively&Eosin (H)&E) Staining to evaluate damage condition and pathological change of cardiac, liver, double kidney and gastric mucosa glands; centrifuging to collect mouse serum, and detecting the levels of alanine Aminotransferase (ALT), aspartic acid Aminotransferase (AST), creatinine (Cr), lactate Dehydrogenase (LDH) and creatine kinase isoenzyme (CK-MB); immunofluorescence staining detection of mouse gastric mucosa gland wall cells H + /K + Influence of atpase; frozen sections were used to detect the level of Reactive Oxygen Species (ROS) in the stomach tissue of mice, and Western Blot was used to detect oxidative stress damage to the stomach tissue of mice.
Example 3.
1. Gastric mucosal gland injury and major organ histopathology.
Mice were sacrificed after the end of dosing, heart, liver, double kidney and stomach tissues of the mice were isolated, fixed with 10% formalin, paraffin embedded, sectioned, H & E stained, and changes in heart, liver, double kidney histopathology and gastric mucosal gland injury were observed.
2. For gastric mucosa wall cell H + /K + Influence of ATPase.
Mice were sacrificed after the end of dosing, gastric tissues of mice were isolated, fixed with 10% formalin, paraffin embedded, sectioned, dewaxed to water, antigen retrieval was performed in an autoclave with the addition of citrate buffer (ph=6.0), blocking solution was blocked for 1H at room temperature, and primary antibody (H) was added + /K + ATPase, 1:100) wet box overnight at 4 ℃, PBST wash 3 times; adding a secondary antibody corresponding to the primary antibody species, incubating for 1h at room temperature, and cleaning the PBST for 3 times; adding diluted DAPI to the sections, covering the groupsThe fabric was reacted at room temperature for 5 minutes, taking care of light protection. Finally, the tablet is sealed by a tablet containing DAPI, and after the tablet is dried in the shade, the picture is taken under a fluorescence microscope.
3. Influence on reactive oxygen species ROS in gastric mucosa.
Mice were sacrificed after dosing, gastric tissues of the mice were isolated, flash frozen, embedded with OCT, frozen sections, and ROS levels of gastric tissues of the mice were detected using ROS staining kit. And diluting the BBox iProbe-beta-body DHE active oxygen fluorescent probe 1000 times by using pure water to prepare a dyeing probe working solution. Diluting 10X cleaning solution by 10 times with pure water to prepare 1X cleaning solution working solution. Unfixed frozen sections of 15 μm thickness to be measured were prepared. At room temperature, 200. Mu.l of a cleaning liquid working solution was carefully added dropwise, the whole slice surface was spread, and the mixture was allowed to stand for 5 minutes. Sucking the cleaning liquid. 100-200 μl of staining probe working solution was added dropwise, and incubated at 37deg.C in an incubator for 30min in the absence of light. Carefully blot the staining solution, wash the sections 3 times with PBS and seal the slide with glycerol. Fluorescence intensity was measured using a fluorescence microscope and photographed at excitation wavelength 535 nm, near emission wavelength 610 nm.
4. Effects on oxidative stress in the stomach tissue of mice.
After the administration is finished, separating stomach tissues, homogenizing, extracting total tissue proteins, quantifying by using BCA proteins, carrying out Western Blot detection on Model groups and traditional Chinese medicine composition groups after tamoxifen induces the expression levels of 8-oxo-dg, HO-1 and Nrf2 proteins in the stomach tissues of mice for 0h, 6h, 24h, 48h and 72h respectively, wherein beta-actin is used as an internal reference.
5. And (3) detecting the biochemical functions of the mouse serum ALT, AST, cr, LDH, CK-MB.
Blood is collected from the eyebox of the mouse, the blood is collected in a sterile EP tube with 1.5ml, kept stand at room temperature for 1 hour, centrifuged at 4 ℃ and 3000g for 15 minutes, and the supernatant is transferred to a corresponding labeled sample tube for preservation, thus obtaining the serum. The mouse serum ALT, AST, cr, LDH, CK-MB levels were assayed on-machine using a fully automated biochemical analyzer according to the kit instructions.
Example 4 experimental results.
1. The traditional Chinese medicine composition improves tamoxifen-induced gastric mucosa gland injury, and H & E staining tissue pathological results are shown in figure 1, compared with a Control group, the Model group mice have obvious gastric mucosa gland gastric mucosa top-bottom injury, wall cells are reduced or even disappear, and glands are expanded. Compared with the Model group, after the traditional Chinese medicine composition is administrated to the stomach, the top-bottom damage of the gastric mucosa of the mice is not obvious, and the number and the morphology of cells of the gastric mucosa wall are basically normal, which indicates that the traditional Chinese medicine composition has the efficacy of improving the gastric mucosa gland damage induced by tamoxifen.
In FIG. 2, after 3 days of intraperitoneal injection of tamoxifen or a blank solution, ddH is administered separately 2 The Chinese medicinal composition is infused for 3 days. The results show that compared with the Control group, the top-bottom damage of the gastric mucosa gland of the Model group mice is obvious, parietal cells are reduced or even disappear, and meanwhile, the glands are expanded, so that the top-bottom damage of the gastric mucosa of the mice with the Chinese medicinal composition for lavage is light, and the number and the morphology of the parietal cells of the gastric mucosa are normal.
2. Traditional Chinese medicine composition for improving tamoxifen-induced gastric mucosal wall cell H + /K + ATPase and results are shown in FIG. 3. H + /K + ATPase plays an important role in maintaining normal structure of gastric mucosal wall cells and in maintaining normal acidic environment in the stomach when H + /K + Under-expression of atpase results in decreased gastric acid secretion and atrophy of gastric mucosa. Compared with Control group, model group and Chinese medicinal composition group mouse gastric mucosa gland wall cell H + /K + The number of ATPase-positive cells was reduced to varying degrees. Compared with Model group, the Chinese medicinal composition group has gastric mucosa gland wall cell H of mice + /K + The number of ATPase positive cells is improved.
3. The results of improving tamoxifen-induced oxidative damage of gastric mucosal glands after treatment with the Chinese medicinal composition are shown in figure 4. Reactive Oxygen Species (ROS) levels are key indicators of oxidative damage caused by normal physiological functions of cells and environmental factors. Thus, reliable measurement of ROS concentration or relative levels is of great importance. By detecting the reactive oxygen species ROS levels in the stomach tissue of mice, the results showed that: compared with the Control group, the gastric mucosa gland reactive oxygen species ROS level of the mice of the Model group is obviously increased. Compared with the Model group, after the traditional Chinese medicine composition is administrated for gastric lavage, the level of Reactive Oxygen Species (ROS) in the gastric mucosa glands of mice is obviously reduced.
4. The traditional Chinese medicine composition reduces oxidative damage of gastric mucosa glands induced by tamoxifen after treatment and enhances the antioxidation effect. 8-hydroxydeoxyguanosine (8-oxo-dg) is the most commonly used biomarker in oxidative damage to DNA. Heme Oxygenase 1 (Heme oxidase-1, HO-1) is an important antioxidant enzyme, and Nrf2 (Nuclear factor erythroid-related factor 2, NFE2L 2) is a transcription factor important for oxidative stress, and can directly regulate HO-1 promoter activity. Thus, the expression levels of 8-oxo-dg, nrf2 and HO-1 proteins were further detected by Western felt. As shown in FIG. 5, compared with the Model group, the Chinese medicinal composition group had the 8-oxo-dg protein expression in the stomach tissue of mice down-regulated after tamoxifen induction for 0h, 6h, 24h, 48h, and 72h, respectively, and the Nrf2 and HO-1 protein expression were up-regulated.
5. Effects of mouse serum ALT, AST, cr, LDH, CK-MB levels.
To further evaluate the safety of the treatment with the Chinese medicinal composition, the mice serum ALT, AST, cr, LDH, CK-MB level was examined for myocardial enzyme, liver function, kidney function injury. The results suggest that the biochemical detection results of myocardial enzymes, liver functions and kidney functions of each group of mice are all within the reference range of normal values (table 1).
Table 1 mouse serum ALT, AST, cr, LDH, CK-MB assay level.
6. Effects of heart, liver, double kidney histopathology in mice.
The histopathological conditions of the organs of the heart, liver and kidney of the mice are observed through H & E staining. The results indicate that Control, model and the traditional Chinese medicine composition groups have the advantages of compact cell arrangement of heart, liver and kidney, clear demarcation, abundant cytoplasm, normal cell morphology, uniform coloring and no obvious abnormality.
Claims (8)
1. The traditional Chinese medicine composition for treating gastric mucogenesis lesions is characterized by comprising the following traditional Chinese medicine components in parts by weight: 9-18 parts of ginseng, 9-18 parts of bighead atractylodes rhizome, 9-18 parts of poria cocos, and 6-9 parts of liquorice (stir-fried).
2. The traditional Chinese medicine composition for treating gastric mucogenesis lesions is characterized by comprising the following traditional Chinese medicine components in parts by weight: 9 parts of ginseng, 9 parts of bighead atractylodes rhizome, 9 parts of poria cocos, and 9 parts of liquorice (stir-fried).
3. The method for preparing a Chinese medicinal composition for treating gastric mucogenesis lesions according to any one of claims 1-2, wherein when the Chinese medicinal composition is an extract, the method comprises the following steps: (1) weighing the raw materials according to the proportion; (2) Soaking the weighed medicinal materials in 70% ethanol with volume of about 3 times of that of the medicinal materials for 12 hours, filtering with filter paper and a funnel, retaining filtrate, and discarding filter residues; (3) And putting the obtained filtrate on a rotary evaporator for rotary evaporation, taking out when the filtrate is in a viscous wall-hanging state, and putting the filtrate in a hot air sterilizing box for evaporating residual alcohol.
4. The method for preparing a Chinese medicinal composition for treating gastric mucogenesis lesions according to any one of claims 1-2, wherein when the Chinese medicinal composition is a powder, the method comprises the following steps: taking the medicine combination according to the weight parts, crushing, sieving with a 10-mesh sieve and a 50-mesh sieve, continuously crushing coarse particles which cannot pass through the 10-mesh sieve, and taking powder between the 10-mesh sieve and the 50-mesh sieve; mixing the above materials, packaging into a packaging bag, and sealing.
5. The method for preparing a Chinese medicinal composition for treating gastric mucometaplasia according to any one of claims 1-2, wherein when the Chinese medicinal composition is a pill, the method comprises the following steps: taking the above medicines according to the parts by weight, crushing, sieving with a 10-mesh and 50-mesh sieve, continuously crushing coarse particles which cannot pass through the 10-mesh sieve, taking powder between the 10-mesh sieve and the 50-mesh sieve, and sun-drying; and (3) taking a proper amount of honey, decocting slowly with small fire, stirring, taking out impurities and floating foam on the surface, raising the temperature to 116-119 ℃, uniformly mixing with the medicinal powder (adding according to the proportion of 1:1.2-1.5), rubbing pills, and packaging and storing the prepared honeyed pills in sealed bags after the prepared honeyed pills are dried at room temperature.
6. The method for preparing a traditional Chinese medicine composition for treating gastric mucogenesis lesions according to any one of claims 1-2, wherein when the traditional Chinese medicine composition is a decoction, the method comprises the following steps: weighing the raw materials according to the proportion; soaking the raw materials in 8-12 times of water for 30min, heating to boil and keeping slight boiling, and separating to obtain a first decoction and residue; adding water 8-10 times of the total weight of the raw materials into the residue obtained after the first decoction, heating to boil, keeping micro-boiling, and separating to obtain a second decoction and residue; and combining the first decoction and the second decoction to obtain the oral solution.
7. The traditional Chinese medicine composition for treating gastric mucometaplasia according to any one of claims 1-2, wherein the traditional Chinese medicine composition for treating gastric mucometaplasia is prepared into decoction, pills, ointment, tablets, capsules, granules, oral solutions and powder.
8. Use of a pharmaceutical composition according to any one of claims 1-2 for the treatment of gastric mucogenic lesions in the preparation of a medicament for the treatment of gastric mucogenic lesions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410148797.3A CN117883493A (en) | 2024-02-02 | 2024-02-02 | Traditional Chinese medicine composition for treating gastric spasmolytic polypeptide expression metaplasia and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410148797.3A CN117883493A (en) | 2024-02-02 | 2024-02-02 | Traditional Chinese medicine composition for treating gastric spasmolytic polypeptide expression metaplasia and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117883493A true CN117883493A (en) | 2024-04-16 |
Family
ID=90651953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410148797.3A Pending CN117883493A (en) | 2024-02-02 | 2024-02-02 | Traditional Chinese medicine composition for treating gastric spasmolytic polypeptide expression metaplasia and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117883493A (en) |
-
2024
- 2024-02-02 CN CN202410148797.3A patent/CN117883493A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503237A (en) | SCUTELLARIABARBATAD. Process for making a purified extract of DON | |
| KR100699790B1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a Lonicera caerulea L. var. edulis extract | |
| CN104840777A (en) | Diabetes treating traditional Chinese medicine preparation and preparation method thereof | |
| Fokunang et al. | Phytochemical screening and in vivo evaluation of antiulcer properties of secondary metabolites in aqueous extracts of Ficus. thonningii Blume tested on Wistar rats | |
| CN101172145A (en) | Medicament for clearing heat, eliminating phlegm, relieving cough smoothing lung and preparation method thereof | |
| CN117883493A (en) | Traditional Chinese medicine composition for treating gastric spasmolytic polypeptide expression metaplasia and preparation method and application thereof | |
| CN105477361B (en) | A kind of Chinese medicine composition preparation method that treating gastritis and preparation | |
| CN109771457A (en) | Purposes of the russule extract in the preparation that preparation treatment and/or prevention high fat diet cause hepatic injury related disease | |
| CN114712478B (en) | Traditional Chinese medicine composition for treating intestinal diseases, preparation and preparation method thereof | |
| CN111419999B (en) | Traditional Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
| CN101229317B (en) | Medicine for removing heat-phlegm, relieving cough, and moistening lung and preparing method thereof | |
| CN108079169A (en) | For preventing and treating the Chinese medicine composition of atherosclerosis and its complication, Chinese medicine preparation and application | |
| CN106309546A (en) | Extract for treating diabetic nephropathy | |
| CN113662975A (en) | Chenopodium quinoa willd extract and application thereof in preparation of medicines and foods for preventing gastric mucosal injury | |
| CN109550035B (en) | New application of traditional Chinese medicine composition in preparation of antidepressant | |
| KR102192586B1 (en) | Phamaceutical composition for treating fatty liver disease and health functional for improving liver function comprising extracts or powder of Pleurotus eryngii var. ferulea (Pf.) | |
| CN103272146B (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
| CN102274332A (en) | Process for preparing Chinese medicinal powder for treating peptic ulcer | |
| CN105477360B (en) | A kind of Chinese medicine composition preparation method that treating gastritis and preparation | |
| CN105477359B (en) | A kind of Chinese medicine composition preparation method that treating gastritis and preparation | |
| CN109876088A (en) | A kind of natural antihypelipidemic preparation playing blood sugar reducing function by adjusting intestinal flora balance | |
| CN105395889B (en) | A kind of Chinese medicine composition preparation method that treating gastritis and preparation | |
| CN115463164B (en) | Preparation method of ephedra root ethyl acetate part, and medicine and application thereof | |
| CN105477364B (en) | A kind of Chinese medicine composition preparation method that treating gastritis and preparation | |
| CN105381259B (en) | A kind of Chinese medicine composition preparation method that treating gastritis and preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |